Immunotherapy Drug Articles & Analysis
11 news found
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
Drug therapy is one of the major modalities for cancer treatment. However, drug resistance may reveal whether it is chemotherapy drugs, targeted drugs, or immunotherapy drugs. ...
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery ...
ByArdigen
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant Immunotherapy platform ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is expanding its scientific advisory board with the appointment of Jeff Sharman, M.D. and Clive Stanway, Ph.D. ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. The data confirm the potential of V-306 for ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. Virometix filled a vacancy in its management team with the ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory Syncytial Virus) ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, is pleased to announce that the Belgian health authority, FAMHP, has approved the company’s clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) ...
Virometix, a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the appointment of Anna Sumeray as Chief Executive Officer. She succeeds Arin Ghasparian, who will remain member of the Board of Directors. The Board of Directors wishes to thank Mr Ghasparian ...